IDEXX Reports 10% Third-Quarter Revenue Growth and Raises 2026 Guidance
IDEXX reported third-quarter 2026 revenue of $1,214 million, up 10% on reported and organic bases. Earnings per diluted share rose 18% to $4.01; adjusted EPS was $3.96 and exceeded analyst expectations.
IDEXX Laboratories, Inc. reported third-quarter 2026 revenue of $1,214 million, representing a 10% increase on both a reported and organic basis. The company achieved earnings per diluted share of $4.01, an 18% increase compared to the previous year. Adjusted earnings per share were $3.96, exceeding analyst expectations.
Growth was driven by the Companion Animal Group, which saw 10% organic growth, and strong performance in veterinary software and diagnostic imaging systems. Additionally, the company raised its full-year 2026 revenue and EPS guidance.